ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2565

Prevalence of Anti-Neutrophil Cytoplasmic Antibodies in Infective Endocarditis: An Analysis of 109 Cases

Alfred Mahr1, Frédéric Batteux2, Sarah Tubiana3, Michel Wolff4, Claire Goulvestre2, Thomas Papo5, François Vrtovsnik6, Isabelle Klein7, Bernard Iung8 and Xavier Duval9, 1Internal Medicine, Hospital Saint-Louis, Paris, France, 2Laboratoire d'Immunologie, Hospital Cochin, Paris, France, 3Clinical Investigation, Hospital Bichat, Paris, France, 4Intensive Care Unit, Hospital Bichat, Paris, France, 5Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 6Nephrology, Hospital Bichat, Paris, France, 7Radiology, University Paris-7, APHP, Bichat Hospital, Paris, France, 8Cardiology, Hospital Bichat, Paris, France, 9Infectious Diseases, Hospital Bichat, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: ANCA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCAs), particularly those directed against proteinase 3 (anti-PR3) or myeloperoxydase (anti-MPO), are considered a highly specific hallmark of ANCA-associated vasculitis. Thus, false-positive ANCA tests have been reported in the context of drug exposure or infection, and several small case studies suggested that ANCAs can be detected in infective endocarditis (IE). This situation, combined with the multisystem protean presentation of IE, may lead to inappropriate diagnosis and therapy. Because the frequency of ANCAs in IE is unknown, we assessed the prevalence of ANCAs in a relatively large number of cases with IE.

Methods: The study was conducted in the framework of a prospective cohort study of consecutive cases with IE launched in 2005 in a single university hospital. Data on the principal demographic, clinical, laboratory (including serum creatinin and hematuria) and microbiological features were collected by a standardized questionnaire. Sera were stored for all patients who gave informed consent for blood sampling. Among the patients for whom sera were stored, we selected those with blood sampled not later than 30 days after the initiation of antibiotic therapy. All selected sera were tested for ANCAs in a central laboratory using indirect immunofluorescence (IIF) assays, and positive results were confirmed by ELISA. IIF involved ethanol-fixed neutrophils and categorized positive tests for C-ANCA (cytoplasmic pattern) or P-ANCA (perinuclear pattern). ELISA for anti-PR3 and anti-MPO specificities involved use of commercially available kits. In addition, we tested all sera for antinuclear antibodies by use of a commercially available indirect immunofluorescence test.

Results: Sera from 109 patients (81 [74%] men, mean age: 57.4 yrs [SD: 15.3]) were tested. All patients fulfilled Duke’s criteria for definite or probable endocarditis, and 33 (30%) had prosthetic valves. The major causative pathogens were Staphylococcus aureus (n = 30), Streptococci (n = 23), Streptococcus bovis (n = 10) and Enterococci (n = 7). C-ANCAs were found in 13 patients (12%), P-ANCAs in 11 (10%) and 1 case (1%) showed both patterns. ELISA revealed anti-PR3 in 4 cases (3%) and anti-MPO in 4 (3%), some with very high titers. The 8 anti-PR3/anti-MPO–positive IE cases involved various pathogens and both native and prosthetic valves. Testing for antinuclear antibodies was positive (titer > 1:160) in 17 (16%) cases.

Conclusion: This study is the first to assess the prevalence of ANCAs in IE and suggests that ANCAs, including those with anti-PR3 or anti-MPO specificities, occur in a significant subset of cases. These observations considerably substantiate the consideration of IE as a potential cause of false ANCA positivity.


Disclosure:

A. Mahr,
None;

F. Batteux,
None;

S. Tubiana,
None;

M. Wolff,
None;

C. Goulvestre,
None;

T. Papo,
None;

F. Vrtovsnik,
None;

I. Klein,
None;

B. Iung,
None;

X. Duval,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-anti-neutrophil-cytoplasmic-antibodies-in-infective-endocarditis-an-analysis-of-109-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology